文献速递皮肤肿瘤

肢端黑色素瘤BRAF状态与免疫检查点分子及空间转录组特征

Immune checkpoint molecules and spatial transcriptome profiles according to BRAF status in acral melanoma.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-06-03

本研究在肢端黑色素瘤组织中检测BRAF、PD-1、LAG-3和TIM-3的免疫组化表达,并通过空间转录组分析BRAF与免疫检查点分子的相关性。结果显示BRAF阳性与PD-1、LAG-3、TIM-3高表达相关,BRAF高组抗肿瘤免疫通路下调、内皮细胞、肥大细胞和中性粒细胞浸润增加。结论提示BRAF突变型肢端黑色素瘤免疫检查点分子表达升高,支持免疫治疗应用。

要点

  • BRAF阳性肢端黑色素瘤中PD-1、LAG-3、TIM-3表达升高。
  • BRAF高表达组抗肿瘤免疫通路显著下调。
  • BRAF突变型肢端黑色素瘤可考虑免疫治疗。

核心结论

  • 肢端黑色素瘤中BRAF突变与免疫检查点分子表达增加相关,支持BRAF突变型患者使用免疫治疗。
  • BRAF突变型肢端黑色素瘤的肿瘤免疫微环境差异可能解释其不良预后。

研究设计与样本

  • 对肢端黑色素瘤组织进行BRAF、PD-1、LAG-3和TIM-3的免疫组化染色。
  • 采用空间转录组分析检测BRAF表达与免疫检查点分子表达的相关性。
  • 比较BRAF高组与BRAF低组的mRNA水平差异表达基因、通路分析和免疫细胞解卷积。
  • 共纳入144例患者。

主要发现

  • 免疫组化和空间转录组分析显示BRAF阳性与PD-1、LAG-3和TIM-3高表达相关。
  • 144例患者中,BRAF(p < 0.01)、PD-1(p < 0.01)、LAG-3(p < 0.01)和TIM-3(p < 0.01)免疫组化阳性与病理亚型、细胞形态、Paget样播散和巢状形成等组织病理学特征显著相关。
  • 空间转录组分析中LAG-3表达水平与BRAF表达水平显著相关(p < 0.01)。
  • BRAF高表达组中抗肿瘤免疫相关通路显著下调。
  • 免疫细胞解卷积显示BRAF高表达组内皮细胞(p = 0.001)、肥大细胞(p = 0.014)和中性粒细胞(p = 0.004)显著增高。

临床怎么用

  • 对肢端黑色素瘤患者评估BRAF状态,BRAF突变型可考虑免疫治疗。
  • BRAF突变型肢端黑色素瘤的免疫微环境特征可能影响预后,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acral melanoma (AM) shows different genomic profiles based on BRAF status, and the data on the association with BRAF and immune checkpoint molecules are lacking. OBJECTIVES: This study aimed to identify the significance of BRAF mutation in AMs, exploring expression patterns of immune checkpoint molecules and transcriptome profiles related to tumour immunity according to BRAF status. METHODS: Immunohistochemical (IHC) staining of BRAF, Programmed death-1 (PD-1), Lymphocyte-activation gene-3 (LAG-3) and T-Cell Immunoglobulin and mucin domain-3 (TIM-3) was performed on AM tissues. Through spatial transcriptome analysis, the correlation between BRAF expression and immune checkpoint molecule expression was examined. Analysis on differentially expressed genes along with pathway analysis and immune cell deconvolution was performed comparing BRAF-high and BRAF-low groups at the mRNA level. RESULTS: In IHC and spatial transcriptome analysis, BRAF positivity was associated with high expression of PD-1, LAG-3 and TIM-3. Among a total of 144 patients, positive IHC results for BRAF (p < 0.01), PD-1 (p < 0.01), LAG-3 (p < 0.01) and TIM-3 (p < 0.01) were significantly associated with histopathologic traits including pathological subtypes, cytomorphology, pagetoid spread and nest formation. In spatial transcriptome analysis, the expression level of LAG-3 showed a significant association with the expression level of BRAF (p < 0.01). Pathways related to anti-tumour immunity were significantly downregulated in the BRAF-high group. In immune cell deconvolution, endothelial cells (p = 0.001), mast cells (p = 0.014) and neutrophils (p = 0.004) were significantly higher in the BRAF-high group. CONCLUSIONS: BRAF mutation in AM is associated with increased expression of immune checkpoint molecules, supporting the use of immunotherapy for BRAF-mutant AM in clinical practice. Different tumour microenvironments regarding tumour immunity in BRAF-mutant AM may explain the poor prognosis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Yang HJ, Choi ME, Kim DH, et al. Immune checkpoint molecules and spatial transcriptome profiles according to BRAF status in acral melanoma. J Eur Acad Dermatol Venereol. 2025. PMID: 40459254. doi:10.1111/jdv.20780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。